Nitroglycerin Prevents Radial Artery Occlusion

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

1706 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-10-31

Study Completion Date

2014-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Trans-radial approach (TRA) has becoming popular and widely adopted over the last decade. However, radial artery occlusion (RAO) continues to be one of the limitation of trans-radial access and potentially limits the radial artery as an access site in the future. Several strategies have been used to decrease the incidence of RAO including the use of anticoagulation, maintenance of patency during hemostasis, or shortening the duration of compression. Currently, there is no data whether vasoactive pharmacological therapy such as nitroglycerin administered intra-arterially at the end of the procedure may reduce the incidence of RAO. It is hypothesized that the addition of nitroglycerin (nitric oxide donor) at the end of a TRA procedure may reduce the incidence of RAO.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of Structure and Function of Radial Artery After Transradial Coronary Intervention

NCT02831322

Intervention Transradial

COMPLETED NA

Topical Nitroglycerine Treatment for Radial Artery Spasm Prevention

NCT02832115

Radial Artery Spasm Angina Coronary Artery Disease

COMPLETED PHASE4

Prevention of Radial Artery Occlusion: Prophylactic Hyperperfusion Evaluation Trial

NCT01564888

Occlusion of Artery

COMPLETED PHASE4

Palmar Arch Insufficiency as a Risk Factor for Radial Artery Occlusion After Transradial Catheterization

NCT03993834

Coronary Artery Disease

COMPLETED

Strategies to Maintain Radial Artery Patency Following Diagnostic Coronary Angiography - Diagnostic Transradial Coronary Angiography Without Systemic Anticoagulatio

NCT04301921

Patients Undergoing Diagnostic Coronary Angiography

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Injury of Radial Artery

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

SINGLE

Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

500 microgram of Nitroglycerin

500 mcg nitroglycerin was given intra-arterially through the sheath at the end of a transradial procedure

Group Type ACTIVE_COMPARATOR

500 microgram of Nitroglycerin

Intervention Type DRUG

500 microgram of Nitroglycerin (in 5 mL saline) given intra-arterially through the sheath at the end of transradial procedure

Saline 5 mL

0,9% Saline 5 mL was given intra-arterially through the sheath at the end of a transradial procedure

Group Type PLACEBO_COMPARATOR

Saline 5 mL

Intervention Type DRUG

Saline 5 mL given intra-arterially through the sheath at the end of transradial procedure

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

500 microgram of Nitroglycerin

500 microgram of Nitroglycerin (in 5 mL saline) given intra-arterially through the sheath at the end of transradial procedure

Intervention Type DRUG

Saline 5 mL

Saline 5 mL given intra-arterially through the sheath at the end of transradial procedure

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

NTG NaCl 0,9% 5mL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Sequential patients undergoing trans-radial catheterization in the institution will be consented to be randomized to receive either 500 microgram nitroglycerin (Group A) or a placebo (Group B) administered intra-arterially through the sheath at the end of the procedure.